טוען...
Does it help that efficacy has been proven once we start discussing (added) benefit?
Since the introduction of benefit assessment to support reimbursement decisions in Germany there seems to be the impression that totally distinct methodology and strategies for decision making would apply in the field of drug licensing and reimbursement. In this article, the position is held that, w...
שמור ב:
| הוצא לאור ב: | Biom J |
|---|---|
| Main Authors: | , |
| פורמט: | Artigo |
| שפה: | Inglês |
| יצא לאור: |
John Wiley and Sons Inc.
2015
|
| נושאים: | |
| גישה מקוונת: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4758384/ https://ncbi.nlm.nih.gov/pubmed/26140608 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/bimj.201400017 |
| תגים: |
הוספת תג
אין תגיות, היה/י הראשונ/ה לתייג את הרשומה!
|